Kaplan-Meier Survival Curves for Gender, Tumor Site, MMR, NLR and other factors
In this study, 65 patients who received immune checkpoint inhibitors were included for survival follow-up to determine PFS. The time from the start of immunotherapy to the occurrence of disease progression or death due to various causes in these patients was defined as PFS. According to different factors (including gender, MMR, tumor site, KRAS status, type of immune checkpoint inhibitor, whether combined with targeted therapy, whether liver metastatic cancer, whether lymph nodes metastases, and NLR level), they were divided into different groups, and the Kaplan-Meier survival curves of each group were plotted separately. The results showed that in the MMR grouping, there was a statistical difference between the PFS survival curves of the two, P =0.029, indicating that patients with dMMR group had a longer PFS and a better patient prognosis than patients with pMMR group. In addition, in the NLR level grouping, there was a statistical difference between the PFS survival curves of the two, P =0.007, indicating that patients in the low NLR group had longer PFS and better patient prognosis than patients in the high NLR group. Finally, there was no statistically significant difference in the PFS survival curves among the groups of gender, tumor site, KRAS status, type of immune checkpoint inhibitor, whether or not it was combined with targeted therapy, whether or not it was hepatic metastatic cancer and whether or not it was lymph nodes metastases,P >0.05, as shown in Figure 1.
Figure 1 Kaplan-Meier Survival Curves for several factors